News & Updates
Showing Pharmacy articles
Showing
Show Multimedia Only

Psoriasis control maintained with less frequent guselkumab dosing
11 Aug 2024
byJairia Dela Cruz
A 16-week dosing interval for the IL-23 inhibitor guselkumab appears to sufficiently keep psoriasis controlled among patients who have achieved complete skin clearance shortly after starting standard treatment with the drug, according to the phase IIIb GUIDE clinical trial.
11 Aug 2024

Belamaf plus pomalidomide/dexamethasone improves PFS in relapsed multiple myeloma
08 Aug 2024
byStephen Padilla
In patients with relapsed/refractory multiple myeloma (RRMM) who received at least one prior line of therapy (LOT), treatment with belantamab mafodotin (belamaf) plus pomalidomide and dexamethasone (BPD) results in statistically significant and clinically meaningful progressive-free survival (PFS) compared with pomalidomide plus bortezomib and dexamethasone (PVD), as shown in the DREAMM-8 study.
08 Aug 2024







